ライフサイエンスコーパス: preoperative chemotherapy

1 Each patient was treated with four cycles of preoperative chemotherapy.

2 ing and histologic assessment of response to preoperative chemotherapy.

3 T10 protocol and therapy with more intensive preoperative chemotherapy.

4 ix patients with stage IIIB disease received preoperative chemotherapy.

5 28% displayed a good histologic response to preoperative chemotherapy.

6 mber and diameter, extrahepatic disease, and preoperative chemotherapy.

7 59.8% of patients received preoperative chemotherapy.

8 ge of the primary, and the administration of preoperative chemotherapy.

9 er resection for colorectal metastases after preoperative chemotherapy.

10 a is possible in many patients after initial preoperative chemotherapy.

11 ncer who underwent resection of CCLM without preoperative chemotherapy.

12 physicians prefer a short course of systemic preoperative chemotherapy.

13 ve histologically positive lymph nodes after preoperative chemotherapy.

14 calendar period of surgery, and response to preoperative chemotherapy.

15 f Pediatric Oncology in Europe in regards to preoperative chemotherapy.

16 the time of diagnosis patients' response to preoperative chemotherapy.

17 ients were treated, and 13 received the full preoperative chemotherapy.

18 re registered in the study, and 138 received preoperative chemotherapy.

19 e operative morbidity and mortality by using preoperative chemotherapy.

20 Two hundred sixteen patients received preoperative chemotherapy, 227 underwent immediate surge

21 6.4%; P=0.037), as well as lower response to preoperative chemotherapy (63.9% vs 85.2%; P=0.006).

22 The regimen with more intensive preoperative chemotherapy achieved a modest increase in

23 carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patient

24 Of 30 patients completing preoperative chemotherapy, all had tumor regression and

25 e excluded, two because they were undergoing preoperative chemotherapy and 11 because of the presence

26 l: 14.9 months for the patients who received preoperative chemotherapy and 16.1 months for those who

27 adequate data , 213 were assigned to receive preoperative chemotherapy and 227 to undergo immediate s

28 was 78% for the regimen with more intensive preoperative chemotherapy and 73% for the control arm.

29 Preoperative chemotherapy and chemoradiation have also b

30 rbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in thi

31 utcomes for 378 patients treated with modern preoperative chemotherapy and hepatectomy were analyzed.

32 nt, and the relationship between response to preoperative chemotherapy and outcome were also evaluate

33 APC and PIK3CA predicts inferior response to preoperative chemotherapy and poor survival in patients

34 Although EPP as part of trimodality therapy (preoperative chemotherapy and postoperative radiation) i

35 of newer chemotherapeutic agents, the use of preoperative chemotherapy and radiotherapy, and the use

36 and PIK3CA mutations in patients undergoing preoperative chemotherapy and resection for colorectal l

37 Pathologic response predicts survival after preoperative chemotherapy and resection of CLM.

38 chemotherapy predicts patient survival after preoperative chemotherapy and resection of colorectal li

39 in WT, in addition to histologic response to preoperative chemotherapy and tumor stage.

40 All patients completed preoperative chemotherapy, and 26 completed preoperative

41 in the surgery-only arm and 62 months in the preoperative chemotherapy arm (hazard ratio, 0.79; 95% C

42 h AJCC stage IIIB extremity STS treated with preoperative chemotherapy between 1986 and 1990 at The U

43 vascular or biliary invasion) are reduced by preoperative chemotherapy, but their impact on survival

44 ic radiation therapy (50 to 60 Gy; arm A) or preoperative chemotherapy (cisplatin/etoposide [PE]; thr

45 No patient in the early era received preoperative chemotherapy, compared with 64 in the late

46 hile preserving renal tissue by intensifying preoperative chemotherapy, completing definitive surgery

47 Preoperative chemotherapy consisted of four courses of h

48 nts (6 months to 18 years) were treated with preoperative chemotherapy consisting of 6 weeks of vincr

49 tion was to administer up to five courses of preoperative chemotherapy consisting of fluorouracil (50

50 Tumor response to preoperative chemotherapy correlates with outcome and co

51 ptor status, histologic grade, and number of preoperative chemotherapy cycles had good discrimination

52 The success of breast conservation after preoperative chemotherapy depends on careful patient sel

53 OS for chemotherapy alone, cystectomy alone, preoperative chemotherapy followed by cystectomy, and cy

54 is made with a biopsy, treatment consists of preoperative chemotherapy followed by definitive surgery

55 lti-institutional randomized trial comparing preoperative chemotherapy followed by surgery with surge

56 ents with primary breast cancer treated with preoperative chemotherapy followed by surgery; have avai

57 In one patient, who had undergone preoperative chemotherapy for a mass that was initially

58 After completing preoperative chemotherapy for a median of 7.1 months (ra

59 status who underwent hepatic resection after preoperative chemotherapy for CCLM (1990 to 2015).

60 ate the feasibility, safety, and efficacy of preoperative chemotherapy for colon cancer.

61 However, there were trends in favor of preoperative chemotherapy for DFS and OS in women less t

62 Preoperative chemotherapy for patients randomly assigned

63 opsy can be performed either before or after preoperative chemotherapy for patients with clinical N0

64 Preoperative chemotherapy for radiologically staged, loc

65 ients whose tumour showed a poor response to preoperative chemotherapy (>/=10% viable tumour) improve

66 tients with objective tumor regression after preoperative chemotherapy had improved survival.

67 ents who had initial tumor size < or = 2 cm, preoperative chemotherapy had no impact on volume of bre

68 al tumor size >2.0 cm, patients who received preoperative chemotherapy had significantly smaller volu

69 The increased use of preoperative chemotherapy has raised new questions conce

70 larger breast tumors, patients treated with preoperative chemotherapy have less extensive resection,

71 0 months for surgery alone and 33 months for preoperative chemotherapy (hazard ratio, 0.80; 95% CI, 0

72 NBC patients treated with anthracycline-only preoperative chemotherapy, high CD73 gene expression was

73 Long-term follow-up confirms that preoperative chemotherapy improves survival in operable

74 Preoperative chemotherapy in operable breast cancer has

75 ally assess benefits and risks of the use of preoperative chemotherapy in patients presenting with co

76 value of an optimal morphologic response to preoperative chemotherapy in patients undergoing chemoth

77 OEO2 is a randomized, controlled trial of preoperative chemotherapy in patients undergoing radical

78 ET is valuable for monitoring the effects of preoperative chemotherapy in patients with locally advan

79 Preoperative chemotherapy, in addition to other common r

80 The degree of tumor necrosis in response to preoperative chemotherapy is a reliable prognostic facto

81 localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 re

82 Preoperative chemotherapy is as effective as postoperati

83 This preoperative chemotherapy is feasible and can also be pr

84 ms' tumour when the histological response to preoperative chemotherapy is incorporated into the risk

85 Preoperative chemotherapy is increasingly being used for

86 resected primary tumor following a period of preoperative chemotherapy is predictive of subsequent ev

87 Preoperative chemotherapy is the conventional primary tr

88 ts with LA/BR PDAC, which includes prolonged preoperative chemotherapy, is associated with a high inc

89 th good histologic response with intensified preoperative chemotherapy, no improvement in EFS was obs

90 A statistically significant impact of preoperative chemotherapy on outcomes was observed in th

91 g those that occurred during the interval of preoperative chemotherapy (one of the five also had a su

92 Preoperative chemotherapy or chemoradiation has been acc

93 ssion correlated with histologic response to preoperative chemotherapy or event-free survival.

94 ephrectomy from 1989 to 2006 did not receive preoperative chemotherapy or radiation therapy and under

95 Significant predictors of SSI included preoperative chemotherapy (OR = 1.94 [95% CI, 1.16-3.25]

96 ed with 91% (90 of 99) of patients following preoperative chemotherapy (p=0.10).

97 Independent of preoperative chemotherapy regimen, optimal morphologic r

98 Preoperative chemotherapy-related hematologic toxicity a

99 ith fluorine-18 fluorodeoxyglucose (FDG) for preoperative chemotherapy response in patients with loca

100 Two did not complete preoperative chemotherapy secondary to cardiovascular to

101 tment approach including standardized 3-drug preoperative chemotherapy, surgical resection within 12

102 tients who underwent hepatic resection after preoperative chemotherapy that included bevacizumab at a

103 Although OS and PFS were higher with preoperative chemotherapy, the differences did not reach

104 lly advanced breast carcinoma (LABC) receive preoperative chemotherapy to provide early systemic trea

105 All 13 patients received preoperative chemotherapy to reduce the size of the prim

106 of the study included pathologic response to preoperative chemotherapy, toxicity, and survival.

107 h of liver resection, malignant indications, preoperative chemotherapy treatment, elements of metabol

108 ilar demographics, diagnoses, comorbidities, preoperative chemotherapy treatments, and extent of part

109 ological response (> 90% tumour necrosis) to preoperative chemotherapy was about 29% with both regime

110 peratively, and 56.3%, 20.5%, and 15.9% when preoperative chemotherapy was administered alone.

111 Preoperative chemotherapy was administered in 68% of cas

112 Compared with cystectomy alone, preoperative chemotherapy was associated with a signific

113 Histologic response to preoperative chemotherapy was determined by morphometric

114 Gradually, the idea of preoperative chemotherapy was extended to include patien

115 Response to preoperative chemotherapy was observed in 29 of 72 patie

116 ted with oxaliplatin and/or irinotecan-based preoperative chemotherapy were eligible for the study.

117 for patients with breast cancer treated with preoperative chemotherapy were reviewed.

118 Complications during preoperative chemotherapy were seen in five patients (tu

119 red fifty-eight patients (38.9%) received no preoperative chemotherapy, whereas 248 patients (61.1%)

120 Preoperative chemotherapy with a combination of cisplati

121 The patient receives preoperative chemotherapy with doxorubicin and cyclophos

122 atients started and 89% (85 of 95) completed preoperative chemotherapy with grade 3-4 gastrointestina

123 This article analyzes the impact of preoperative chemotherapy with mitomycin, ifosfamide, an

124 trials have again demonstrated tolerance to preoperative chemotherapy with no increase in operative

125 We report on feasibility of preoperative chemotherapy with or without radiation ther

126 in 26 countries who had received 4 weeks of preoperative chemotherapy with vincristine and actinomyc

127 his study was to determine if more intensive preoperative chemotherapy would increase the proportion